SBLO.F Stock Overview
A contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Shin Nippon Biomedical Laboratories, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥16.97 |
| 52 Week High | JP¥16.97 |
| 52 Week Low | JP¥16.97 |
| Beta | 0.11 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBLO.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 1.7% |
| 1Y | n/a | 9.0% | 26.3% |
Return vs Industry: Insufficient data to determine how SBLO.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how SBLO.F performed against the US Market.
Price Volatility
| SBLO.F volatility | |
|---|---|
| SBLO.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SBLO.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SBLO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 1,360 | Ryoichi Nagata | www.snbl.co.jp |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services.
Shin Nippon Biomedical Laboratories, Ltd. Fundamentals Summary
| SBLO.F fundamental statistics | |
|---|---|
| Market cap | US$667.50m |
| Earnings (TTM) | US$37.87m |
| Revenue (TTM) | US$185.23m |
17.6x
P/E Ratio3.6x
P/S RatioIs SBLO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBLO.F income statement (TTM) | |
|---|---|
| Revenue | JP¥26.85b |
| Cost of Revenue | JP¥12.66b |
| Gross Profit | JP¥14.19b |
| Other Expenses | JP¥8.70b |
| Earnings | JP¥5.49b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 131.85 |
| Gross Margin | 52.83% |
| Net Profit Margin | 20.44% |
| Debt/Equity Ratio | 83.5% |
How did SBLO.F perform over the long term?
See historical performance and comparison